Overview

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-05-01

Target enrollment:

Participant gender:

Summary

This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.

Phase:

PHASE2

Details

Lead Sponsor:

BioNTech SE

Treatments:

Carboplatin
Etoposide
Paclitaxel
Topotecan